Advancis infectious news

AVNC restructured and reduced its headcount by 38% from 87 to 54 employees. Included among the 33 cuts were Barry Hafkin, SVP and CSO; Joseph Rogus, SVP of technical operations; Colin Rowlings, SVP of pharmaceutical R&D; Donald Anderson, VP of discovery; James Bruno, VP of sales; and Robert Guttendorf, VP of pharmacology and biopharmaceutics. The move follows the failure of two Phase III trials of AVNC's Amoxicillin Pulsys to treat pharyngitis/tonsillitis due to Group A streptococcal infections in adults and children (see BioCentury, July 25). ...